For the third time in the company’s history, the Danish biotech company Saniona, mostly known for its research in treatment of obesity and diabetes, has spun off activities in a separate company.
Saniona spins out cancer project in new firm
Scandion Oncology, a spinoff from Saniona, has high hopes for the company’s candidate drug for the treatment of cancer. The drug has already been through clinical phase I and the plan is to begin phase II clinical trials on cancer patients within two years.
![The photo does not depict the Scandion Oncology drug. | Foto: Colourbox](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article5673933.ece/ALTERNATES/schema-16_9/COLOURBOX5018178.jpg)
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app